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Abstract
Background The sentinel lymph node (SLN) procedure
has the potential to provide relevant improvement in nodal
staging in colon cancer patients. However, there remains
room for improvement for SLN identification and sensi-
tivity. Therefore, the objective of the present investigation
was to analyze factors influencing the success of the SLN
procedure in colon cancer patients.
Methods One hundred seventy-four consecutive colon
cancer patients were prospectively enrolled in this multi-
center study and underwent in vivo SLN procedure with
isosulfan blue 1 % followed by open standard oncologic
colon resection. Several patient-, tumor-, and procedure-
related factors possibly influencing the SLN identification
and sensitivity were analyzed.
Results Sentinel lymph node identification rate and
accuracy were 89.1 and 83.9 %, respectively. Successful
identification of SLN was significantly associated with the
intraoperative visualization of blue lymphatic vessels
(p \ 0.001) and with female gender (p = 0.024). True
positive SLN results were significantly associated with
higher numbers of SLN (p = 0.026) and with pN2 stage
(p = 0.004). There was a trend toward better sensitivity in
patients with lower body mass index (BMI) (p = 0.050).
Conclusions The success of the SLN procedure in colon
cancer patients depends on both procedure-related factors
(intraoperative visualization of blue lymphatic vessels,
high number of SLN identified) and patient factors (gender,
BMI). While patient factors can not be influenced, intra-
operative visualization of blue lymphatics and identifica-
tion of high numbers of SLN are key for a successful SLN
procedure.
Introduction
The sentinel lymph node (SLN) procedure has the potential
to provide relevant improvement in nodal staging in colon
cancer patients. Several multicenter studies, including our
own, have shown that in-depth and focused analysis of
SLN reveals small nodal tumor infiltrates in about 15 % of
patients that were diagnosed node-negative in the initial
routine hematoxylin & eosin (H&E) analysis [1–7]. While
these findings are promising, there is still room for
improvement regarding overall SLN identification rate and
sensitivity. However, it remains unclear whether these
results are influenced by patient-, tumor-, or procedure-
related factors. Therefore, the objective of this study was to
analyze factors influencing the SLN identification rate and
sensitivity in patients with resectable colon cancer.
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Patients and methods
The ‘‘Swiss Prospective, Multicenter Study Sentinel Lymph
Node Procedure in Colon Cancer’’ (www. clinicaltrials.gov:
NCT00826579) enrolled 174 patients with biopsy-proven,
resectable colon cancer (stage I–III according to the Amer-
ican Joint Cancer Commission [AJCC], 6th Edition) from
May 2000 through December 2006. The study was approved
by all ethical committees of the participating centers, and
it was conducted in compliance with the Declaration of
Helsinki. All patients gave written informed consent. All
patients underwent open surgery with an in vivo SLN pro-
cedure with isosulfan blue 1 % (without radioisotopes)
according to a standardized protocol as previously described
[8]. Three levels of each SLN were stained with H&E and
immunostained with the pancytokeratin marker AE1/AE3 if
H&E was negative. Results regarding technical details,
identification rate, accuracy, and upstaging rate have been
reported elsewhere [6].
Factors influencing the success of the procedure
Our prospectively collected database was queried to
evaluate the importance of the following factors possibly
influencing the SLN identification and accuracy: gender,
localization of the primary tumor, previous abdominal
surgery, intraoperative visualization of blue lymphatic
vessels, presence of lymphovascular invasion, T stage, N
stage, nodal status in H&E, grading, AJCC stage, age, body
weight, height, body mass index (BMI), volume of dye
injected, tumor size, number of SLN identified, total
number of lymph nodes analyzed, number of positive
lymph nodes in H&E.
Statistical analysis
Categorical variables were analyzed with the Fisher’s exact
test. For continuous variables, Student’s t-test was used.
Statistical analyses were performed with SPSS 13.0 for
Macintosh (SPSS Inc., Chicago, IL). A p value \0.05 was
considered to be significant. All p values were two-sided.
Accuracy was defined as (true positive ? true negative)/all
patients with SLN identification; sensitivity was defined as
true positive/(true positive ? false negative).
Results
Overall, 174 patients were enrolled in the study. The
median age was 73.7 years (range: 27.3–93.0 years);
54.6 % of the patients were men. The SLN identification
rate was 89.1 % (155/174 patients; Fig. 1), the accuracy
was 83.9 % (130/155 patients), and the sensitivity of the
procedure was 55.4 % (31/56 patients). Of 104 stage I and
II patients, 16 (15.4 %) were upstaged after identification
of small nodal tumor infiltrates in the SLN [6].
Factors influencing the success of the procedure
Numerous factors from our prospective database were
assessed to determine whether they influence the SLN
identification rate and sensitivity. Successful identification
of SLN was significantly associated with the intraoperative
visualization of blue lymphatic vessels (p \ 0.001) and
with female gender (p = 0.024; Table 1). True positive
SLN results were significantly associated with higher
numbers of SLN (p = 0.026) and with pN2 stage
(p = 0.004; Table 1). There was a trend toward better
sensitivity in patients with lower BMI (p = 0.050).
Discussion
The present study—one of the first in the literature—
provides evidence that the success of the in vivo sentinel
lymph node procedure in colon cancer patients is influ-
enced by both procedure-related and patient-related factors.
Sentinel lymph node identification significantly depended
Fig. 1 Comparative groups. FN false negative group, ID identifica-
tion group, NID non-identification group, pts patients, SLN sentinel
lymph node, TN true negative group, TP true positive group, w/o
without
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Table 1 Analysis of influencing factors
Parameter Sentinel lymph node Sentinel lymph node
Identified (n = 155) Not identified (n = 19) True positive (n = 45) False negative (n = 25)
n % n % P value n % n % P value
Gender 0.024 0.098
Male 80 51.6 15 78.9 29 64.4 11 44.0
Female 75 48.4 4 21.1 16 35.6 14 56.0
Localization of primary tumor 0.949 0.375
Right colon 67 43.2 8 42.1 14 31.1 12 48.0
Left colon 28 18.1 3 15.8 12 26.7 5 20.0
Sigmoid colon 60 38.7 8 42.1 19 42.2 8 32.0
Previous abdominal surgery 0.884 0.591
No 87 56.1 11 57.9 24 53.3 15 60.0
Yes 68 43.9 8 42.1 21 46.7 10 40.0
Blue lymphatics identified intraoperatively \0.001 0.803
No 14 9.7 10 52.6 3 7.0 2 8.7
Yes 130 90.3 9 47.4 40 93.0 21 91.3
Lymphovascular invasion 0.618
L0 123 79.4 16 84.2 28 62.2 16 64.0
L1 32 20.6 3 15.8 17 37.1 9 36.0
T stage 0.714 0.713
pT1 11 7.1 1 5.3 1 2.2 0 0.0
pT2 23 14.8 3 15.8 3 6.7 2 8.0
pT3 99 63.9 14 73.7 32 71.1 20 80.0
pT4 22 14.2 1 5.3 9 20.0 3 12.0
N stage 0.834 0.004
pN0 99 63.9 11 57.9 0 0.0 0 0.0
pN1 38 24.5 5 26.3 16 51.6 22 88.0
pN2 18 11.6 3 15.8 15 48.4 3 12.0
Nodal status in H&E 0.610
Negative 99 63.9 11 57.9 0 0.0 0 0.0
Positive 56 36.1 8 42.1 45 100.0 25 100.0
Grading 0.106 0.937
G1 0 0.0 0 0.0 0 0.0 0 0.0
G2 112 72.3 17 89.5 32 71.1 18 72.0
G3 43 27.7 2 10.5 13 28.9 7 28.0
Stage 0.870 n/a
I 29 18.7 3 15.8 1 2.2 0 0.0
II 70 45.2 8 42.1 13 28.9 0 0.0
III 56 36.1 8 42.1 31 68.9 25 100.0
Parameter Median Range Median Range P value Median Range Median Range P value
Age (years) 73.7 27.3–92.4 76.4 57.3–93.0 0.198 74.3 47.6–88.2 70.5 47.4–92.4 0.270
Body weight (kg) 73.6 39.2–130 82.0 52.0–106 0.167 72.0 45.0–100 70.0 57.0–128 0.176
Height (cm) 168 145–189 170 155–194 0.126 169.5 152–185 167 150–186 0.527
BMI (kg/cm2) 25.6 15.9–44.3 25.8 21.6–37.6 0.671 24.2 15.9–33.1 25.4 20.5–44.3 0.050
Volume of dye (ml) 2.0 0.2–10.0 2.0 1.0–10.0 0.436 2.0 0.3–10.0 2.0 1.0–6.0 0.515
Tumor size (cm) 4.1 1.5–16.0 3.7 1.0–8.5 0.101 4.0 1.5–9.5 4.5 2.5–8.0 0.456
Total no. of SLN identified 3 1–20 0 0–0 n/a 3 1–20 2 1–10 0.026
Total no. of LN analyzed 24 5–62 16 7–67 0.091 23 12–62 29 11–54 0.598
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on the intraoperative visualization of blue-stained lym-
phatic vessels. This finding is quite intuitive, as the surgeon
often has to follow the blue-stained lymphatics to identify
the SLN. However, blue lymphatics are not always easily
discerned, particularly in a fatty mesentery. This problem
might be overcome with a second, submucosal blue dye
injection ex vivo and careful dissection of the mesentery
[9], or by using newer lymphatic tracers that can be visu-
alized with near-infrared fluorescence light [10]. Moreover,
in the present study, patients with true positive SLN results
had significantly more SLN identified than patients with
false negative results, underlining the importance of care-
fully looking for and identifying several SLN during the
procedure. In fact, two thirds of the patients with false
negative results had fewer than four SLN identified intra-
operatively (data not shown). In this respect, it is note-
worthy that the median number of SLN in colon cancer
patients is usually higher than that, for instance, in breast
cancer [6, 11]. It is important that all patients underwent
open colon cancer resection. Therefore, our results cannot
necessarily be generalized to patients undergoing laparo-
scopic procedures. Additionally, even though the SLN
procedure leads to a better staging in colon cancer patients
(upstaging rate 15.4 %) [6, 12], due to the high false
negative rate the nodal staging must not solely rely on the
SLN results.
It must be emphasized that several tumor-related factors,
like localization of the primary tumor, tumor size, pT-
stage, and lymphovascular invasion, did not influence
either the SLN identification rate or the sensitivity.
Therefore, the SLN procedure seems to be applicable
irrespective of tumor stage and size. This is in line with
findings from a recent meta-analysis in which no differ-
ences in sensitivity were found for different T-stages [5]. In
the present investigation, however, pN2 patients showed
significantly more true positive SLN results than pN1
patients. Obviously, the likelihood of identifying a positive
SLN increases with the number of positive nodes.
Patient-related factors might also play an important role.
For example, patients with lower BMI showed a statistical
trend toward true positive results (p = 0.050). Moreover,
successful identification of SLN was significantly associ-
ated with female gender (p = 0.024). Other patient-related
factors, however, did not influence the success of the SLN
procedure. Finally, the success of the procedure was not
influenced by a history of previous abdominal surgery
either, indicating that the SLN procedure might safely be
performed after previous abdominal surgery.
Only two other multicenter studies have investigated
factors affecting the success of the SLN procedure:
Bembenek et al. [1] found a significantly better identifi-
cation rate and—in line with our results—sensitivity with
lower BMI, an improved identification rate with lympho-
vascular invasion, and—similar to our results—an
improved sensitivity with increasing numbers of involved
lymph nodes. In the study by Nissan et al. [13] identifi-
cation of C3 SLN was an independent predictor of a true
positive SLN result, also is in line with our findings,
whereas tumor-replaced lymph nodes were predictive of
false negative SLN results.
Interestingly, patients with SLN identification showed a
trend toward a higher number of analyzed and reported
lymph nodes than patients without SLN identification
(median 24 versus 16; p = 0.091). By successfully per-
forming the SLN procedure, the pathologist’s attention to
nodal staging is increased, thus spurring him or her to find
more lymph nodes, which is among the positive ‘‘side
effects’’ of the SLN procedure.
In summary, the success of the SLN procedure in colon
cancer patients depends on both procedure-related and
patient-related factors. While the latter cannot be influ-
enced, intraoperative visualization of blue lymphatics and
identification of high numbers of SLN are key for a suc-
cessful SLN procedure.
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Table 1 continued
Parameter Median Range Median Range P value Median Range Median Range P value
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BMI body mass index, H&E hematoxylin and eosin staining, LN lymph nodes, n/a not applicable
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